Does Adding Omentopexy to Cruroplasty Improve Outcomes After Sleeve Gastrectomy in Patients with Sliding Hiatal Hernia?”

Posterior Cruroplasty Alone Versus Posterior Cruroplasty with Full-Length Omentopexy During Laparoscopic Sleeve Gastrectomy in Patients with Sliding Hiatal Hernia: A Prospective Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR202603517591648

Enrollment

100

Registered

2026-03-31

Start date

2023-03-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digestive System Surgery

Interventions

Posterior Cruroplasty Alone During Laparoscopic Sleeve Gastrectomy

Posterior Cruroplasty Omentopexy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adult patients (=18 years) scheduled for primary laparoscopic sleeve gastrectomy Presence of small-to-moderate sliding hiatal hernia (=5 cm axial displacement) confirmed preoperatively Mild gastroesophageal reflux disease (GERD) defined as symptoms controlled or partially controlled with intermittent or once-daily proton pump inhibitor therapy Los Angeles grade A esophagitis or no esophagitis on preoperative endoscopy Hernia anatomy deemed suitable for tension-free posterior cruroplasty Provision of written informed consent

Exclusion criteria

Exclusion criteria: Moderate-to-severe esophagitis (Los Angeles grades B–D) Barrett’s esophagus Reflux-related strictures Severe bile reflux gastritis Suspected or documented esophageal motility disorders Clinical indication favoring Roux-en-Y gastric bypass Large (>5 cm) or paraesophageal hiatal hernia Anticipated need for mesh reinforcement Previous foregut or bariatric surgery

Design outcomes

Primary

Measure	Time frame
Composite functional adverse outcome at 12 months defined as any of the following: (1) Radiologically confirmed hiatal hernia recurrence or intrathoracic sleeve migration; (2) Clinically significant GERD requiring continuous daily proton pump inhibitor therapy or endoscopic esophagitis in symptomatic patients; (3) Symptomatic functional sleeve stenosis or torsion confirmed by imaging or endoscopy.	—

Measure

Time frame

Composite functional adverse outcome at 12 months defined as any of the following: (1) Radiologically confirmed hiatal hernia recurrence or intrathoracic sleeve migration; (2) Clinically significant GERD requiring continuous daily proton pump inhibitor therapy or endoscopic esophagitis in symptomatic patients; (3) Symptomatic functional sleeve stenosis or torsion confirmed by imaging or endoscopy.

—

Secondary

Measure	Time frame
Operative duration;Intraoperative blood loss;Early postoperative nausea and vomiting;Early dysphagia;Length of hospital stay;GERD-HRQL score;Daily PPI use;Radiologic sleeve position;Endoscopic intervention; Readmission;Revisional surgery	—

Countries

Egypt

Contacts

Public ContactGamal Abdalla

Lecturer of General Surgery Faculty of Medicine Ain Shams University

GamalAbdalla@med.asu.edu.eg+201065754272

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026